Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: A new framework for 3D printed medical devices in Australia

The rise of 3D printing technology in medicine and healthcare is challenging existing regulatory frameworks as higher risk 3D printed medical devices are developed. Tracy Lu, senior associate for Allens in Sydney, explains that Australia is at the forefront of dealing with this regulatory reassessment.

The definition of a custom-made device – under the Therapeutic Goods Regulations – is currently sufficiently broad to capture a range of medical devices, from those that are adapted from a standard template to suit a patient’s anatomy to devices which are truly one-off.

Custom-made devices are currently subject to limited conformity assessment procedures and are exempt from premarket assessment, although they are not exempt from post-market monitoring.

The existing regulatory regime for custom-made devices was developed when the risk associated with such devices was low. With the advent of medical 3D printing technology, however, more and more higher risk devices (which would otherwise attract higher risk classifications and stringent premarket oversight) are being released to the market.

In response to this change in environment, the TGA has put forward five proposals in a recent consultation paper.

First, a new umbrella term “personalised medical devices” is proposed, which will include the subcategories “custom made”, “customised” and “patient-specific”. Custom made devices would be limited to those intended for the sole use of a particular patient and for which there is no commercially available alternative. This definition also excludes mass produced devices adapted to suit specific requirements of any professional user and patient-specific devices.

Customised devices would refer to devices supplied by a manufacturer with a specific intended purpose that must be adapted or assembled, in accordance with the manufacturer’s validated instructions, to suit an individual patient. Patient-specific devices would refer to devices based on a standard template model that is matched to a patient’s anatomy, or by using the full anatomic features from patient imaging.

At a recent 3D printing in Medicine and Healthcare industry event hosted by Allens, a representative of the TGA noted that the changes to the definitions are the most significant changes in this consultation paper. A new vocabulary would allow all the relevant stakeholders to have meaningful conversations regarding 3D printing in the context of medical device regulations.

Second, given the proposed changes to custom-made devices, the more limited conformity assessment procedures would now apply to a narrower subset of devices and the TGA would also have the power to enter and inspect manufacturing sites. Next, for customised devices, the TGA proposes that a manufacturer’s liability would be limited only to adaptations which are carried out in accordance with the manufacturer’s validated instructions. Further, the TGA recognises that some healthcare providers may have in-house 3D printing capability which allows them to produce devices which would fall under the current definition of custom made devices and the new proposed definition of patient-specific devices. This means that the exemptions for custom made devices would no longer apply. Therefore, where the patient-specific device is of a lower risk classification, TGA proposes to exempt such providers from regulation as a manufacturer.

Fourth, devices that are intended by the manufacturer to be used to record diagnostic images (for example 3D scanners) would have the same classification as X-rays. And finally, medical devices incorporating materials of human origin would be regulated as medical devices rather than biologicals (for which different regulatory requirements apply), so that there is consistency of approach across medical devices.

It is positive to see the Australian regulator take a proactive role in addressing the regulatory challenges posed by medical 3D printing. TGA in fact chairs the issue of personalised medical devices for the International Medical Device Regulators Forum, which aims to harmonise regulatory approaches across a number of jurisdictions. The TGA’s recent proposals, however, do not cover technical considerations for designing, manufacturing and testing such devices – it is also important to develop adequate quality controls over those aspects to ensure the safety and wellbeing of patients.

Posted on: 29/11/2017 UTC+08:00


News

Brisbane-based Oventus has raised A$7.6 million (US$5.8 million) selling 13.8 million shares at A$0.55 per share. The deal was heavily oversubscribed with strong support from new and existing institutional and sophisticated investors.
After postponing its up to US$150 million IPO in March 2015, Malaysian-based primary healthcare provider Qualitas Medical Group is gearing up to launch another IPO attempt on the SGX in the first quarter of next year. The size remains the same.
Ryman Healthcare, New Zealand’s largest listed retirement village operator, has bought Victoria University of Wellington’s former Karori campus which will be converted into a retirement village with independent and serviced apartments and a care centre. Although financial terms have not been disclosed, it is estimated to have been sold for NZ$20 million (US$13.8 million).
Singapore-based medtech company Advent Access has raised S$2.6 million (US$1.9 million) pre-Series A financing led by Accuron MedTech, the largest medical device company in southeast Asia. It is the largest pre-Series A financing round by a medtech startup across the region.
Hang Seng-listed Golden Meditech has taken a 50% stake in Japanese real estate management company ASA for ¥425 million (US$3.7 million). Magnum Opus, which is owned by Kam Yuen, Golden Meditech’s chairman and controlling shareholder, holds the remaining 50%.
In the latest move of their long-running patent dispute, New Zealand-based medical device manufacturer Fisher & Paykel Healthcare has filed a patent infringement proceeding in the Federal Court of Australia against ResMed, the Australian manufacturer of products for the treatment of sleep disorders, and several of its related companies.
Singapore-based managed healthcare provider Fullerton Health has acquired a 60% stake in the Intellicare Group, one of the leading managed care providers in the Philippines. Financial terms have not been disclosed.
Vital Healthcare Property Trust, the only NZSX-listed healthcare property fund, has acquired Eden Rehabilitation Hospital in Cooroy, Queensland for A$23.8 million (US$17.9 million).



Analysis

The world’s first healthcare development impact bond aimed at reducing the number of maternal and newborn deaths in Rajasthan, India, launched last week.
The rise of 3D printing technology in medicine and healthcare is challenging existing regulatory frameworks as higher risk 3D printed medical devices are developed. Tracy Lu, senior associate for Allens in Sydney, explains that Australia is at the forefront of dealing with this regulatory reassessment.
In the third part of his series about operating healthcare companies across the APAC region, Marcus Pitt, managing partner of Fortuna Corpus Asia, focuses on the opportunities in the Philippines.
The promise of a bottom in Singapore’s office market has caused its ranking as an investment market to soar from next-to-bottom last year to third in this year’s “Emerging Trends in Real Estate Asia Pacific 2018” report, a real estate forecast jointly published by the Urban Land Institute (ULI) and PwC.
Kamal Brar, vice president and general manager of Asia Pacific for data software company Hortonworks, looks at how data analytics can provide effective and affordable healthcare in Singapore.
The latest Sun Life Financial Asia Diabetes Awareness Study reveals an alarming knowledge gap in diabetes. A third of Asian women who are or were pregnant in the past three years are unaware of the risk of developing gestational diabetes in pregnancy, while one in seven births in Asia is currently affected by gestational diabetes.
Gan Kim Yong, Singapore’s minister for health, explains why the private sector needs to get behind the National Electronic Health Record System.
Business leaders in Asia Pacific’s healthcare industry are showing urgency in embracing the fourth industrial revolution, according to the Microsoft Asia Digital Transformation Survey. More than three-quarters of them believe that they need to transform to a digital business to enable future growth and yet only a quarter said that they have a full digital strategy in place today.


Civica

Podcasts

AON

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices